On May 19, 2025, Telomir Pharmaceuticals, Inc. raised $3 million through a direct equity sale at $3.00 per share, signaling strong support from its largest shareholder and funding their upcoming IND submission for a rare disease. This fundraising occurred at an 18% premium to the previous closing share price of $2.54.